Status:
UNKNOWN
REGulatory T Cells in Autism Induced by Maternal Immune Activation
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Autism Spectrum Disorder
Eligibility:
All Genders
3-15 years
Phase:
NA
Brief Summary
Autism Spectrum Disorders (ASD) represent a heterogeneous clinical entity of neurodevelopmental disorders affecting around 1% of the general population (Lord et al. 2020). There is currently no curati...
Detailed Description
The aim of the REGAIN project will be to study in detail the cellular populations involved in the development of MIA-mediated autistic symptoms in humans. Based on both our preliminary meta-analysis ...
Eligibility Criteria
Inclusion
- Patients with positive diagnosis of ASD according to DSM-5 (APA, 2015);
- Age at inclusion between 3 and 15 years;
- Informed consent signed by both parents and oral agreement in principle given by the subject;
- Patients affiliated to a social security system
Exclusion
- Patients with severe/profound intellectual disability;
- Uncontrolled epileptic seizures;
- Maternal infection during pregnancy with a pathogen with a known direct cerebral cytotoxic effect (CMV);
Key Trial Info
Start Date :
January 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2026
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT06169111
Start Date
January 1 2024
End Date
January 1 2026
Last Update
December 13 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Robert Debré Hospital
Paris, France, 75019